Tg Therapeutics Stock Today
| TGTX Stock | USD 30.71 0.02 0.07% |
PerformanceWeak
| Odds Of DistressVery Low
|
TG Therapeutics is trading at 30.71 as of the 16th of February 2025; that is 0.07 percent decrease since the beginning of the trading day. The stock's open price was 30.73. TG Therapeutics has under 5 % chance of experiencing financial distress over the next 2 years but had a somewhat weak performance during the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of December 1995 | Category Healthcare | Classification Health Care |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. The company has 155.66 M outstanding shares of which 26.88 M shares are at this time shorted by private and institutional investors with about 10.16 trading days to cover. More on TG Therapeutics
Moving against TGTX Stock
TGTX Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTG Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand TG Therapeutics' financial leverage. It provides some insight into what part of TG Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
TG Therapeutics (TGTX) is traded on NASDAQ Exchange in USA. It is located in 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560 and employs 319 people. TG Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.78 B. TG Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 155.66 M outstanding shares of which 26.88 M shares are at this time shorted by private and institutional investors with about 10.16 trading days to cover.
TG Therapeutics currently holds about 195.71 M in cash with (31.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45.
Check TG Therapeutics Probability Of Bankruptcy
Ownership AllocationTG Therapeutics secures a total of 155.66 Million outstanding shares. Over half of TG Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check TGTX Ownership Details
TGTX Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Deep Track Capital, Lp | 1.7 M | ||
| Bank Of America Corp | 2024-09-30 | 1.7 M | |
| Hood River Capital Management Llc | 2024-09-30 | 1.6 M | |
| Jpmorgan Chase & Co | 2024-09-30 | 1.4 M | |
| Northern Trust Corp | 2024-09-30 | 1.4 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.3 M | |
| Fmr Inc | 2024-09-30 | 1.2 M | |
| 683 Capital Management Llc | 2024-09-30 | 1.1 M | |
| Two Sigma Investments Llc | 2024-09-30 | 1.1 M | |
| Blackrock Inc | 2024-09-30 | 22 M | |
| Vanguard Group Inc | 2024-09-30 | 15.4 M |
TG Therapeutics Historical Income Statement
TGTX Stock Against Markets
TG Therapeutics Corporate Executives
Elected by the shareholders, the TG Therapeutics' board of directors comprises two types of representatives: TG Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TGTX. The board's role is to monitor TG Therapeutics' management team and ensure that shareholders' interests are well served. TG Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TG Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.